About Adlai Nortye

Adlai Nortye

Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs in the field of oncology/immuno-oncology. Our mission is to improve patient lives by developing differentiated, innovative medicines that help people live better and longer.

 We have 23 patents granted and 7 PCT published. With extensive experience in peptide and protein drugs, we have expanded our expertise into small molecules and therapeutic antibodies. Through close collaboration with global partners, we have successfully positioned ourselves in the fields of immuno-oncology/oncology and have several programs ongoing from early pre-clinical to phase 3 ready. 

Development History

"Sinopep Pharmaceutical" was established in 2004.

The fund from Science and Technology Ministry in 2009.

Recognized as a “National High-tech Enterprises” in 2009.

The 11th Polypeptide Technology Application Award in 2010.

Shareholding system reform and renamed “Adlai Nortye Biopharma” in 2016.

Listed on NEEQ in Feb 21, 2017. (Stock Code:870946)

Terminated a listing on NEEQ in Mar, 2018.

Raising $53 million in Series B Round of financing in June, 2018.

Opened the new USA headquarters  in New Jersey in Sept. 25, 2018.